Dr. James Howard, MD
Neurology (Neurology Physician)
At a glance
- Medical school
- University of Vermont College of Medicine (1974)
- Years since graduation
- 52
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1974Medical school: University of Vermont College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NC license 23383
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pyridostigmine Bromide Other prescribers in Chapel Hill, NC | 29 |
| Mycophenolate Mofetil Other prescribers in Chapel Hill, NC | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 53 payments worth $78,030 in total to this clinician.
| Argenx US, Inc. | $29,966 |
|---|---|
| UCB SA | $27,297 |
| Alexion Pharmaceuticals, Inc. | $11,209 |
| Regeneron Pharmaceuticals, Inc. | $6,725 |
| H. Lundbeck A S | $2,100 |
| Vertex Pharmaceuticals Incorporated | $467 |
| UCB, Inc. | $266 |
| Consulting Fee | $51,978 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $14,688 |
| Travel and Lodging | $8,039 |
| Honoraria | $2,100 |
| Food and Beverage | $1,226 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB SA Jul 4, 2025 | Consulting Fee | $11,748 |
| Argenx US, Inc. Oct 1, 2025 | Consulting Fee VYVGART · Immunology | $9,375 |
| UCB SA Jul 4, 2025 | Consulting Fee | $8,250 |
| Argenx US, Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART HYTRULO · Neurology | $8,125 |
| UCB SA Oct 16, 2025 | Travel and Lodging travel to Barcelona, Spain · in-kind | $5,943 |
| Alexion Pharmaceuticals, Inc. Oct 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $4,720 |
| Argenx US, Inc. Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $3,438 |
| Argenx US, Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $3,125 |
| Alexion Pharmaceuticals, Inc. Jan 9, 2025 | Consulting Fee SOLIRIS · Rare Disease | $2,950 |
| Alexion Pharmaceuticals, Inc. Jul 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,950 |
All 32 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Dec 12, 2025 | Consulting Fee VYVGART; VYVGART HYTRULO · Immunology | $2,500 |
| Regeneron Pharmaceuticals, Inc. Nov 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $643 |
| Argenx US, Inc. Nov 13, 2025 | Consulting Fee VYVGART · Immunology | $2,500 |
| Alexion Pharmaceuticals, Inc. Oct 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $4,720 |
| Alexion Pharmaceuticals, Inc. Oct 27, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to San Francisco, CA Company’s descriptionConsulting Expenses | $340 |
| Alexion Pharmaceuticals, Inc. Oct 27, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to San Francisco, CA Company’s descriptionConsulting Expenses | $72.00 |
| UCB SA Oct 16, 2025 | Travel and Lodging travel to Barcelona, Spain · in-kind | $5,943 |
| UCB SA Oct 16, 2025 | Travel and Lodging travel to Barcelona, Spain · in-kind | $1,356 |
| Argenx US, Inc. Oct 1, 2025 | Consulting Fee VYVGART · Immunology | $9,375 |
| Vertex Pharmaceuticals Incorporated Sep 29, 2025 | Consulting Fee | $216 |
| Argenx US, Inc. Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $3,438 |
| Vertex Pharmaceuticals Incorporated Jul 21, 2025 | Consulting Fee | $251 |
| UCB SA Jul 4, 2025 | Consulting Fee | $11,748 |
| UCB SA Jul 4, 2025 | Consulting Fee | $8,250 |
| H. Lundbeck A S Jul 3, 2025 | Honoraria | $2,100 |
| Alexion Pharmaceuticals, Inc. Jul 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,950 |
| UCB, Inc. Jun 5, 2025 | Travel and Lodging travel to San Dieg, CA | $13.98 |
| Argenx US, Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $3,125 |
| Argenx US, Inc. May 12, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Diego, CA | $313 |
| Argenx US, Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART HYTRULO · Neurology | $8,125 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $1,000 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $750 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $500 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $500 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $500 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $500 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $500 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $500 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $375 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $375 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $375 |
| Alexion Pharmaceuticals, Inc. Jan 9, 2025 | Consulting Fee SOLIRIS · Rare Disease | $2,950 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $424,088 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab)…
Argenx US, Inc. - Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
UCB SA · Completed · NCT04225871 - A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular mya…
Argenx US, Inc. - A Phase 3, Open label, Single arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab Administered Intravenously in Pediatric Participants (6 to 18 years of age) …
Alexion Pharmaceuticals, Inc. - A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis.
Argenx US, Inc. - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB SA · Completed · NCT05514873 - Open-label uncontrolled trial to evaluate pharmacokinetics, pharmacodynamics, safety and activity of efgartigimod in children from 2 to less than 18 years of age with generalized myasthenia gravis
Argenx US, Inc. - A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB SA · Completed · NCT06471361 - Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.